Tel:: +49 (0)241 95 163 153
Fax:: +49 (0)241 95 163 155
E-Mail:: orders@anticorps-enligne.fr

Pour une meilleure utilisation, nous vous conseillons d’activer Javascript dans votre navigateur.

SET Nuclear Oncogene (SET) Peptide

SET Reactivité: Humain Hôte: Lapin BP

N° du produit ABIN2764137

Aperçu rapide pour SET Nuclear Oncogene (SET) Peptide (ABIN2764137)

Antigène

SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Origine

Humain

Source

Lapin

Application

Blocking Peptide (BP)

SET Nuclear Oncogene (SET) peptide
SET Reactivité: Humain, Boeuf (Vache) Hôte: Synthetic BP, Imm

SET Nuclear Oncogene (SET) peptide
SET Reactivité: Mammifères Hôte: Synthetic BP, IHC, WB

SET Nuclear Oncogene (SET) (N-Term) peptide
SET Reactivité: Humain Hôte: Synthetic BP, IHC, WB, IP

SET Nuclear Oncogene (SET) peptide
SET Reactivité: Humain Hôte: Synthetic BP, BI

Restrictions

For Research Use only
Stock

-20 °C
Antigène

SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Sujet

Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

Vous êtes ici: